Insider trade

Travere Therapeutics (TVTX): Director sold ~$304K

Gary A Lyons, Director at Travere Therapeutics, sold ~$304K of Travere Therapeutics shares.

~$304K
Approx. value · 21K sh @ $14.35
70K
Holds after · shares reported
Traded
Oct 4, 2024
Filed
Oct 4, 2024

What stands out in this filing

  • The sale was 23.3% of the shares this insider held before it; the filing reports 69,821 shares afterwards.
  • 21,179 shares at an average of $14.35 each, as reported on the form.
  • Footnote references a pre-arranged trading plan (Rule 10b5-1).

Calculated by OQRO from this filing and the public records it holds. Facts about the record, not a reason for the trade and not a signal.

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 4, 2024 · this disclosureInsiderDirector sold ~$304K of TVTX shares in the open market

What came next

  1. Oct 4, 2024InsiderDirector sold ~$285K of TVTX shares in the open market
  2. Nov 25, 2024InsiderOfficer sold ~$221K of TVTX shares in the open market
  3. Dec 26, 2024InsiderOfficer sold ~$258K of TVTX shares in the open market
  4. Jan 3, 2025InsiderOfficer sold ~$39K of TVTX shares in the open market
  5. Jan 6, 2025InsiderOfficer sold ~$8.3K of TVTX shares in the open market
  6. Jan 22, 2025Insider · 6 peopleInsiders: 6 sales (~$368K)
  7. Jan 23, 2025InsiderDirector sold ~$320K of TVTX shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Travere Therapeutics

For Travere Therapeutics, OQRO holds 4 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TVTX page.

Other recent filings by Gary A Lyons, Director

The full history of Gary A Lyons, Director is on the profile page.

How this filing works

Explore the data

Common questions

Which Travere Therapeutics (TVTX) insider traded, and how much?

Gary A Lyons, Director at Travere Therapeutics, sold ~$304K of Travere Therapeutics shares. 21K shares at $14.35.

When did it happen, and when was it made public?

Traded: Oct 4, 2024. Filed: Oct 4, 2024.

What stands out in this filing?

The sale was 23.3% of the shares this insider held before it; the filing reports 69,821 shares afterwards. 21,179 shares at an average of $14.35 each, as reported on the form. Footnote references a pre-arranged trading plan (Rule 10b5-1).

Is the dollar amount exact?

It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.

Where does this information come from?

From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Travere Therapeutics recently?

For Travere Therapeutics, OQRO holds 4 insider filings (SEC Form 4 or Form 144) dated in the last 90 days. They are listed on the TVTX page.

Does this mean TVTX stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Travere Therapeutics

Everything OQRO holds on this company is on its TVTX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data